BioNTech SE

🎗 Not every breast cancer journey looks the same.

For people living with metastatic breast cancer, treatment can become part of everyday life and options may change over time.

Here are 5 reasons why continued research matters, during #BreastCancerAwarenessMonth and every day.

Lung cancer is not one disease.

Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain.

Watch 👇

#LungCancer #CancerResearch

📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer.
🔗 Learn more: bit.ly/4h5DjqL
#LungCancer #WCLC26

We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer.

🔗 Learn more: bit.ly/4gaKY7W

#LungCancer #Oncology #WCLC26 #BioNTech

📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲

𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:

bit.ly/4h9thXn

We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more.

Explore the many: bit.ly/3TuyK13

#WorldLungCancerDay

At #ASCO26, we presented interim data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating an investigational PD-L1 x VEGF-A bispecific immunomodulator in 1L squamous and non-squamous #NSCLC.

At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: bit.ly/4voJn42

#BioNTech #WomensCancer #GynecologicOncology

Tomorrow at #ELCC26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.

Tomorrow at #ELCC26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews

At the #ELCC2026, we will present new clinical data from our late-stage portfolio across various #lungcancer subtypes and lines of treatment, reinforcing the transformative potential of our treatment approaches in this critical area.

👉bit.ly/3NEw5zp

#nsclc #esclc

📢 JPM 2026|Strategic areas of focus

Oncology milestones in 2026:
- 7 late-stage data readouts
- 6 Phase 3 clinical trial initiations expected
- Focus on high-incidence indications, such as lung and breast cancer

📰 bit.ly/3YY5I9L
🎥 bit.ly/3YY5I9L
#JPM2026

Tomorrow at #SABCS25, Dr. Schmid will share the study design of the global phase 3 ROSETTA Breast-01 trial evaluating a PD-L1 x VEGF-A bispecific antibody plus chemotherapy in PD-L1 negative TNBC.

Join the poster session at 12:30pm CST in Exhibit Hall.

🔬 At #SABCS25, we shared interim global Phase 2 data from our investigational bispecific antibody program in metastatic #TNBC with our partner @bmsnews

Learn more in our press release: bit.ly/48CnnrC

#BreastCancerResearch #OncologyScience #BioNTech

Tomorrow at #SABCS25, Dr. Schmid will present preliminary data from a global multicohort phase 2 trial of a PD-L1 x VEGF-A bispecific antibody plus chemotherapy for 1L/2L+ locally advanced/metastatic TNBC.

Today, together with OncoC4, we announced data on an investigational selective Treg modulator candidate in patients with advanced sqNSCLC.

Learn more in our press release: bit.ly/4oGMM9U

#LungCancer #NACLC25

Global interim Phase 2 data in extensive-stage small cell lung cancer presented at #WCLC25:

Investigational approach designed to target PD-L1 and VEGF-A in a single molecule.

Full PR: bit.ly/3I1dZVs

Small cell lung cancer is a key focus at #BioNTech with multiple trials across disease stages. At #WCLC25, we share global interim Phase 2 data on our PD-L1xVEGF-A bispecific antibody candidate in extensive-stage small cell lung cancer.

We are partnering with @bmsnews to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 investors.biontech.de/news-releases/…

At #BioNTech, we’re looking forward to #ASCO25, presenting oncology pipeline progress: mRNA cancer immunotherapies, ADCs, and next-gen immunomodulators and targeted therapies.

🗓 May 30 – June 3 | Chicago
📍 Booth #35165

#CancerResearch #ImmunoOncology #OncologyInnovation